AR128145A1 - Formulación farmacéutica de polvo seco para inhalación y proceso de preparación - Google Patents
Formulación farmacéutica de polvo seco para inhalación y proceso de preparaciónInfo
- Publication number
- AR128145A1 AR128145A1 ARP220103630A ARP220103630A AR128145A1 AR 128145 A1 AR128145 A1 AR 128145A1 AR P220103630 A ARP220103630 A AR P220103630A AR P220103630 A ARP220103630 A AR P220103630A AR 128145 A1 AR128145 A1 AR 128145A1
- Authority
- AR
- Argentina
- Prior art keywords
- ethyl
- dry powder
- lactose
- acid
- powder pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 3
- 229960001375 lactose Drugs 0.000 abstract 3
- 239000008101 lactose Substances 0.000 abstract 3
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 150000004682 monohydrates Chemical class 0.000 abstract 2
- 239000000843 powder Substances 0.000 abstract 2
- PZPFLTPEDAIBBZ-UHFFFAOYSA-N 2-chloro-4-phenyl-1-(trifluoromethyl)benzene Chemical group C1=C(Cl)C(C(F)(F)F)=CC=C1C1=CC=CC=C1 PZPFLTPEDAIBBZ-UHFFFAOYSA-N 0.000 abstract 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 abstract 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 230000002612 cardiopulmonary effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 229960001021 lactose monohydrate Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a formulaciones farmacéuticas de polvo seco, que comprenden ácido (5S)-{[2-(4-carboxifenil)etil][2-(2-{[3-cloro-4-(trifluorometil)bifenil-4-il]metoxi}fenil)etil]-amino}-5,6,7,8-tetrahidroquinolin-2-carboxílico de fórmula (1), preferiblemente en forma de una de sus sales o solvatos o hidratos, preferiblemente ácido (5S)-{[2-(4-carboxifenil)etil][2-(2-{[3-cloro-4-(trifluorometil)bifenil-4-il]metoxi}fenil)etil]-amino}-5,6,7,8-tetrahidroquinolin-2-carboxílico monohidrato I de fórmula (1-M-I) o ácido (5S)-{[2-(4-carboxifenil)etil][2-(2-{[3-cloro-4-(trifluorometil)bifenil-4-il]metoxi}fenil)etil]-amino}-5,6,7,8-tetrahidroquinolin-2-carboxílico monohidrato II de fórmula (1-M-II) en combinación con un portador de lactosa, que comprende lactosa monohidrato como mezcla de lactosa gruesa y lactosa fina, y al proceso de manufactura de dichas formulaciones farmacéuticas de polvo seco y su aplicación para usar en el tratamiento de trastornos cardiopulmonares, tales como hipertensión arterial pulmonar (PAH), hipertensión pulmonar tromboembólica crónica (CTEPH) e hipertensión pulmonar (PH) asociada con enfermedad pulmonar crónica (PH grupo 3) tal como hipertensión pulmonar en la enfermedad pulmonar obstructiva crónica (PH-EPOC) e hipertensión pulmonar con neumonía intersticial idiopática (PH-IIP).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21218160 | 2021-12-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR128145A1 true AR128145A1 (es) | 2024-03-27 |
Family
ID=79230655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220103630A AR128145A1 (es) | 2021-12-29 | 2022-12-28 | Formulación farmacéutica de polvo seco para inhalación y proceso de preparación |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR128145A1 (es) |
TW (1) | TW202342035A (es) |
WO (1) | WO2023126438A1 (es) |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
EA201390060A1 (ru) | 2010-07-09 | 2013-07-30 | Байер Интеллектуэль Проперти Гмбх | Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
SI2875003T1 (sl) | 2012-07-20 | 2017-03-31 | Bayer Pharma Aktiengesellschaft | Nove 5-aminotetrahidrokinolin-2-karboksilne kisline in njihova uporaba |
US9624214B2 (en) | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
MX2022014655A (es) | 2020-05-20 | 2022-12-15 | Bayer Ag | Proceso para preparar (5s)-5-({2-[4-(butoxicarbonil)fenil]etil}[2- (2-{[3-cloro-4'-(trifluorometil)[bifenil]-4-il]metoxi}fenil)etil] amino)-5,6,7,8-tetrahidroquinolin-2-carboxilato de butilo. |
-
2022
- 2022-12-28 TW TW111150501A patent/TW202342035A/zh unknown
- 2022-12-28 AR ARP220103630A patent/AR128145A1/es unknown
- 2022-12-28 WO PCT/EP2022/087955 patent/WO2023126438A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW202342035A (zh) | 2023-11-01 |
WO2023126438A1 (en) | 2023-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR086745A1 (es) | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida | |
ES2646834T3 (es) | Inhibidores de autotaxina y usos de los mismos | |
PE20191744A1 (es) | Derivados de tirosinamida como inhibidores de rho-quinasa | |
JP2010530847A5 (es) | ||
BRPI0515081B8 (pt) | composto, processo para a preparação de um sal de guanidino trifluormetilaroil amida, processo para a preparação de um fenil amino pirido pirimidina, composições farmacêuticas e processos para preparar (3,5-bis trifluormetil)-n-[4-metil-3-(4-piridin-3-il-pirimidin-2-ilamino)-fenil]-benzamida | |
HRP20110807T1 (hr) | Supstituirani pirimidodiazepini korisni kao plk1 inhibitori | |
NZ590268A (en) | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | |
AR089134A1 (es) | Arilos y heteroarilos biciclicos inhibidores de los canales de sodio | |
SI2303270T1 (en) | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceutical products | |
JP2016517432A5 (es) | ||
CO6251286A2 (es) | Sales amino del acido [4, 6-bis(dimetilamino)-2-(4-(4-trifluorometil)benzamido)bencil)pirimidin-5-il]acetico, composiciones farmaceuticas de las mismas y sus usos para el tratamiento de enfermedades mediadas por crth-2 | |
SV2010003770A (es) | Composicion y proceso- 356 | |
RU2010116293A (ru) | Алкилтиопиримидины в качестве антагонистов crth2 | |
MX2022014655A (es) | Proceso para preparar (5s)-5-({2-[4-(butoxicarbonil)fenil]etil}[2- (2-{[3-cloro-4'-(trifluorometil)[bifenil]-4-il]metoxi}fenil)etil] amino)-5,6,7,8-tetrahidroquinolin-2-carboxilato de butilo. | |
JP2013520466A5 (es) | ||
AR128145A1 (es) | Formulación farmacéutica de polvo seco para inhalación y proceso de preparación | |
NZ602710A (en) | Use of novel pan-cdk inhibitors for treating tumors | |
UY37987A (es) | Procedimiento para la preparación de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3- metilbutanoil]amino}fenil)-3-ácido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmacéutico. | |
BR112019012515A2 (pt) | antagonistas de integrina | |
RU2014118574A (ru) | Производные фенилгуанидина | |
AR128147A1 (es) | Procedimiento para la preparación del ácido (5s)-[2-(4-carboxifenil)etil][2-(2-[3-cloro-4-(trifluorometil)bifenil-4-il]metoxifenil)etil]amino-5,6,7,8-tetrahidroquinolina-2-carboxílico y sus formas cristalinas para su uso como compuesto farmacéuticamente activo | |
CY1112480T1 (el) | Χρηση παραγωγων συμπυκνωμενης πυριμιδινης για τη θεραπεια αυτοανοσων και φλεγμονωδων ασθενειων | |
PE20231441A1 (es) | Cocristal de un inhibidor de cdk | |
US20110288133A1 (en) | Histone deacetylase inhibitors | |
US9199947B2 (en) | Biaryl-propionic acid derivatives and their use as pharmaceuticals |